Rituximab for the first-line t

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J

Record ID 32011000783

English

Authors' recommendations: The addition of rituximab to CVP, CHOP and MCP is likely to be clinically effective in the first-line treatment of stage III–IV FL. The cost per QALY gained is estimated to be < £25,000 for all three comparisons under our base-case assumption and is considerably lower if first-line rituximab maintenance is not assumed. The main uncertainties in terms of influencing the ICER relate to the effectiveness of rituximab retreatment (i.e. resistance) and the effect of salvage treatment in patients previously treated with anthracycline regimens. Assumptions were made and the best evidence identified was used when appropriate and available. Therefore, results have to be interpreted in line with the assumptions made and the quality of the evidence available.

Details

Project Status: Completed

Year Published: 2012

URL for published report: http://www.hta.ac.uk/2392

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

MeSH Terms

Antibodies, Monoclonal, Murine-Derived
Lymphoma, Follicular
Skin Diseases
Technology Assessment, Biomedical

Contact

Organisation Name: NIHR Health Technology Assessment programme

Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK

Contact Name: journals.library@nihr.ac.uk

Contact Email: journals.library@nihr.ac.uk

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.